Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Recommendation of “Buy” from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have received an average recommendation of “Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $66.00.

Several analysts recently weighed in on MAZE shares. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. HC Wainwright lifted their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st.

Maze Therapeutics Trading Up 1.3%

NASDAQ MAZE opened at $26.40 on Friday. Maze Therapeutics has a fifty-two week low of $9.73 and a fifty-two week high of $53.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The stock has a 50 day simple moving average of $29.21 and a two-hundred day simple moving average of $37.59. The stock has a market cap of $1.46 billion, a P/E ratio of -10.43 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. On average, analysts forecast that Maze Therapeutics will post -2.74 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 25,582 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total value of $665,643.64. Following the completion of the transaction, the chief executive officer owned 350,987 shares in the company, valued at $9,132,681.74. This trade represents a 6.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the transaction, the insider owned 10,503 shares of the company’s stock, valued at approximately $266,461.11. The trade was a 41.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 119,502 shares of company stock worth $4,246,639. 5.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada lifted its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Maze Therapeutics in the 4th quarter valued at approximately $39,000. Ameritas Investment Partners Inc. lifted its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.